

1 **Human leishmaniasis vaccines: use cases, target population and potential global**  
2 **demand**

3

4 Stefano Malvolti<sup>1</sup>, Melissa Malhame<sup>1</sup>, Carsten Mantel<sup>1</sup>, Epke A. Le Rutte<sup>2</sup>, Paul M.Kaye<sup>3</sup>

5

6 <sup>1</sup> *MMGH Consulting, Zurich, Switzerland*

7 <sup>2</sup> *Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute,*

8 *Basel, Switzerland; Department of Public Health, Erasmus MC, University Medical Center*

9 *Rotterdam, Rotterdam, The Netherlands,*

10 <sup>3</sup> *York Biomedical Research Institute, Hull York Medical School, University of York,*

11 *Heslington, York, United Kingdom*

12

13 *Corresponding authors: [malvoltis@mmglobalhealth.org](mailto:malvoltis@mmglobalhealth.org) (ORCID iD: 0000-0003-0146-*

14 *1127); [paul.kaye@york.ac.uk](mailto:paul.kaye@york.ac.uk) (ORCID iD: 0000-0002-8796-4755)*

15

16

17 **Short title:** Analysis of the global demand for leishmaniasis vaccines

18

19 **Keywords:** leishmaniasis, visceral leishmaniasis, cutaneous leishmaniasis, post-kala-azar

20 dermal leishmaniasis, vaccine, use cases, demand, forecast

21

22

23 **Abstract**

24 The development of vaccines against one or all forms of human leishmaniasis remains  
25 hampered by a paucity of investment, at least in part resulting from the lack of well-  
26 evidenced and agreed estimates of vaccine demand. Starting from the definition of 4 main  
27 use cases (prevention of visceral leishmaniasis, prevention of cutaneous leishmaniasis,  
28 prevention of post-kala-azar dermal leishmaniasis and treatment of post-kala-azar dermal  
29 leishmaniasis), we have estimated the size of each target population, focusing on those  
30 endemic countries where incidence levels are sufficiently high to justify decisions to adopt a  
31 vaccine. We assumed a dual vaccine delivery strategy, including a wide age-range catch-up  
32 campaign before the start of routine immunisation. Vaccine characteristics and delivery  
33 parameters reflective of a target product profile and the likely duration of the clinical  
34 development effort were considered in forecasting the demand for each of the four  
35 indications. Over a period of 10 years, this demand is forecasted to range from 310-830  
36 million doses for a vaccine preventing visceral leishmaniasis and 557-1400 million doses for  
37 a vaccine preventing cutaneous leishmaniasis under the different scenarios we simulated. In a  
38 scenario with an effective prophylactic visceral leishmaniasis vaccine, demand for use to  
39 prevent or treat post-kala-azar dermal leishmaniasis would be more limited (over the 10 years  
40 ~160,000 doses for prevention and ~7,000 doses for treatment). Demand would rise to  
41 exceed 330,000 doses, however, in the absence of an effective vaccine for visceral  
42 leishmaniasis. Because of the sizeable demand and potential for public health impact, a  
43 single-indication prophylactic vaccine for visceral or cutaneous leishmaniasis, and even more  
44 so a cross-protective prophylactic vaccine could attract the interest of commercial developers.  
45 Continuous refinement of these first-of-their kind estimates and confirmation of country  
46 willingness and ability to pay will be paramount to inform the decisions of policy makers and

47 developers in relation to a leishmaniasis vaccine. Positive decisions can provide a much-  
48 needed contribution towards the achievement of global leishmaniasis control.

49

## 50 **Author Summary**

51 The leishmaniasis are potentially vaccine-preventable diseases of global importance, yet no  
52 vaccines for human use have attained registration. This work sheds lights on the potential size  
53 of demand for a human vaccine for the prevention of visceral and cutaneous leishmaniasis as  
54 well as for the prevention and treatment of post-kala-azar dermal leishmaniasis. The analysis  
55 is grounded in the definition of vaccine use cases which, by transparently defining different  
56 applications of the vaccines in the immunisation programs, provides the basis for defining the  
57 target populations and vaccine characteristics. The output of this work, the first-of-its-kind  
58 for leishmaniasis, fills a critical information gap and will provide policy makers and vaccine  
59 developers with important insights into the public health relevance of a human leishmaniasis  
60 vaccine and the strengths of its commercial value proposition. Ultimately this research aims  
61 to inform future decisions on disease prioritization and on investments by key stakeholders,  
62 as well as to identify areas for further research.

63

## 64 **Introduction**

65 Neglected tropical diseases (NTDs) impose a significant health and economic burden on the  
66 world's poorest populations and nations [1]. The latest Global Burden of Disease analysis for  
67 2019 (GBD 2019) [2] estimates that the 20 NTDs recognised by the World Health  
68 Organization (WHO) account for 62.9 million disability-adjusted life years (DALYs) lost and  
69 up to 1.25 million deaths annually. A growing number of those NTDs are currently or may  
70 soon become vaccine-preventable, including Yellow Fever, Rabies, Ebola, Malaria and  
71 Dengue. Yet globally, vaccine development for NTDs progresses at a snail's pace [3], limited  
72 by scientific challenges in target antigen identification, the lack of correlates of protection  
73 and often unsuitable animal models. In addition, the lack of data on potential market size and  
74 value creation reduces financial incentives for vaccine developers to invest in those diseases  
75 [4].

76  
77 In commercial vaccine development efforts, the size of the target population, the revenue  
78 potential, the required investment, the clinical development feasibility and the regulatory  
79 feasibility are the most influential drivers of decisions [5]. An in-depth understanding of the  
80 target populations and of the likely demand are critical inputs for those decisions; this is even  
81 more important in the case of NTDs that disproportionately affect low and lower-middle  
82 income countries with limited fiscal space. Before proceeding with the clinical development  
83 of vaccines for these diseases, commercial developers seek validation of the potential  
84 financial return that can be generated by taking them to market. Beyond vaccine developers,  
85 policy makers, donors and those responsible for regional health systems also need to take into  
86 account the size of the target populations and of the demand for a newly introduced vaccine.  
87 This will determine the public health impact in terms of reduction of mortality and morbidity  
88 and the financial resources required to implement the vaccination program. In low-and lower-

89 middle income countries, those resources may be provided by the public budget or benefit  
90 from direct or indirect donor support (e.g., via Gavi, The Vaccine Alliance (Gavi)).  
91  
92 Among the NTDs, leishmaniasis ranks highly in terms of both mortality and morbidity.  
93 According to the GBD 2019, between 498,000 and 862,000 new cases of all forms of  
94 leishmaniasis are estimated to occur each year [2] resulting in up to 18,700 deaths and up to  
95 1.6 million DALYs lost [2]. The leishmaniasis are a group of diseases caused by infection  
96 with a protozoan parasite of the genus *Leishmania* (*L. Leishmania* spp and *L. Viannia* spp).  
97 Visceral leishmaniasis (VL; kala azar) is a systemic disease affecting the internal organs and  
98 is usually fatal if untreated [6]. Transmission of VL may be zoonotic (*L. infantum*) or  
99 anthroponotic (*L. donovani*). Although new treatment modalities for VL in South Asia  
100 (notably single dose liposomal amphotericin B; AmBisome®) have considerably improved  
101 patient experience and outcome, with reported cure rates of up to 95% [7], treatment in other  
102 regions remains predominantly based on pentavalent antimonials [8], drugs with a number of  
103 severe limitations in convenience and outcome. Post-kala-azar dermal leishmaniasis (PKDL)  
104 is a stigmatizing disease that usually follows treatment of VL caused by *L. donovani*. PKDL  
105 patients carry a significant socio-economic and psychosocial burden. In addition, the skin of  
106 PKDL patients is a site of parasitism and data derived from xenodiagnosis [9] [10] lends  
107 support to the long held view that PKDL patients play a pivotal role in the interepidemic  
108 transmission of VL [11] [12].  
109  
110 Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis affecting humans.  
111 This disease is considered to be a zoonosis, with the exception of *L. tropica*, which in certain  
112 areas is an anthroponotic disease. Healing of localised CL is usually achieved within 3 to 18  
113 months without intervention, though sterile immunity is not thought to be achieved.

114 Nevertheless, CL carries a significant burden of psychosocial risk that, once accounted for  
115 and added to the GBD estimates could lead to estimates of DALYs lost which are up to 10  
116 times higher than current figures [13]. Chemotherapeutic options for CL have changed little  
117 in over 50 years [14]; those medicines remains expensive and questions are still unanswered  
118 about their effectiveness and safety[15]. Once cured, protection against reinfection is  
119 believed to be the norm [16] [17] and this supports the argument that vaccine-induced  
120 protection should be achievable. Localised lesions can evolve into more severe disease  
121 characterized by metastasis to mucosal sites (mucocutaneous leishmaniasis; MCL) or the  
122 occurrence of multiple (>10) discrete lesions (disseminated cutaneous leishmaniasis; DSL).  
123 Rarely, parasites may grow uncontrolled in diffuse lesions across the skin (diffuse cutaneous  
124 leishmaniasis; DCL).

125  
126 The availability of vaccines against one or more forms of leishmaniasis could provide an  
127 affordable way to reduce mortality and morbidity, addressing the above-mentioned  
128 constraints. Vaccines may be deployed to prevent disease (i.e., prophylactically) or used as  
129 alternatives to or in conjunction with existing drugs (i.e., as therapeutic vaccines) for  
130 prevention of primary disease or prevention of secondary sequelae. Practical considerations  
131 including for example population at risk or alternative treatment options would dictate the  
132 relative value or prophylactic vs therapeutic vaccines. While the public health need for a  
133 vaccine exists, clinical development efforts have been limited. Numerous vaccine candidates  
134 have been evaluated in preclinical models of disease [18] but few have progressed to the  
135 clinical trial stage [19]. Currently, only one therapeutic clinical trial is ongoing  
136 (Clinicaltrials.gov NCT03969134), and a clinical-grade genetically attenuated live *L. major*  
137 vaccine is due to be manufactured in 2021 [20] to support future trials. Recent progress  
138 towards the development of a controlled human challenge model for CL [21] [22] may also

139 provide a stimulus for the clinical development of other candidate vaccines. However, the  
140 absence of a consensus on the size of the target populations, the paucity of data to support an  
141 indication for use in each disease state and the lack of realistic demand scenarios are likely  
142 determinants of the scarce interest from the pharmaceutical industry and philanthropic  
143 donors. Estimates of the total burden of leishmaniasis have been difficult due to the  
144 prevailing poor knowledge of the geographical distribution of the diseases. A further  
145 difficulty in burden estimation is the epidemic nature of the disease, leading to significant  
146 interannual variation in disease burden [23]. Those factors have made the definition of a  
147 reliable demand forecast for a leishmaniasis vaccine very challenging.

148

149 To address this critical gap, we developed a first in-depth demand forecast for a leishmaniasis  
150 vaccine that indicates that prophylactic vaccines for visceral and cutaneous leishmaniasis  
151 could have not only a solid public health value proposition but also, subject to countries  
152 confirming their interest for the vaccine and willingness to pay, a commercial potential that  
153 can attract the interest of vaccine developers and manufacturers.

154

## 155 **Methods**

156 To develop the leishmaniasis vaccine demand forecast we employed established population-  
157 based forecasting methods [24] [25] [26]. We started from the definition and estimate of the  
158 target populations for a leishmaniasis vaccine based on the use cases for such vaccine, and  
159 the evolving epidemiology of the disease. We then simulated the potential reached  
160 populations by assessing and by defining a set of assumptions on the sequence of adoption of  
161 the vaccine in endemic countries and the impact of the introduction of the vaccine on those  
162 populations. Finally, we developed the demand forecast by translating these data into doses  
163 of vaccine required, taking into account vaccine characteristics, immunisation schedule and

164 specific programmatic issues. The logical framework of the methodology is represented in

165 **Figure 1.**

166

167 **Use cases definition**

168 To identify the main use cases, defined as “*the specific situation(s) in which a product or a*

169 *service could potentially be used to accomplish a defined goal*”<sup>1</sup>, a workshop was held

170 bringing together researchers involved in the development of leishmaniasis vaccines and

171 therapies, public health professionals and other key opinion leaders<sup>2</sup>. The clinical

172 manifestations of the disease and the treatment goals, differentiated by prophylaxis (primary

173 prevention), prevention of the development of PKDL and treatment of VL, CL or PKDL

174 (therapeutic), were identified as key determinants of the use cases for a leishmaniasis

175 vaccine. Consensus emerged on the factors most likely to require and / or trigger alternative

176 approaches and distinct pathways to disease control. Vector species and subspecies as well as

177 geography were deemed potentially relevant dimensions in future refinement of the use cases.

178

179 **Estimating the target populations**

180 The target populations for the prevention of VL and CL were defined as the populations at

181 risk of these diseases . For the prevention of VL (PKDL) and the treatment of PKDL, the

182 target population was defined based on VL incidence and PKDL prevalence, respectively.

183 Data for these populations are limited and often inconsistent in terms of geographical and

---

<sup>1</sup> The concept of use case was originally developed in software and systems engineering, to describe a list of actions or steps defining the interactions between an actor and a system to achieve a goal.

<sup>2</sup> The workshop took place in May 2019 at the Wellcome Trust in London with the participation of: Jorge Alvar (DNDi), Simon Croft (LSHTM), Tom Evans (Vaccitec), Nirmal Kumar Ganguly (ICMR), Birgitte Giersing (WHO), Bethan Hughes (Wellcome Trust), Christiane Juhls (Molgen), Paul Kaye (Univ. of York), Greg Matlashewski (McGill), Ahmed Musa (Sudan MOH), Richard Muscat (Wellcome Trust), Steve Reed (IDRI).



184 temporal coverage. Therefore, estimates were defined through an iterative process that started  
185 with the identification of the geographies at risk (whether entire countries or specific regions)  
186 followed by the collection of the available global, national and regional data. Estimates  
187 resulting from different sources were further scrutinized and used to define an estimate with  
188 upper and lower range limits to serve as a “base” case.

189

190 *Population at risk for VL.* 25 higher-risk countries are classified by the WHO as “high burden  
191 countries” or those with incidence above 10/10,000 according to latest estimates from the  
192 GBD of 2019 [2] (see **Supplementary Text**). A lower national inclusion threshold was used  
193 compared to the 1/10,000 indicated as the national target for the elimination of leishmaniasis  
194 as a public health problem, to reflect the heterogenous disease occurrence within each  
195 country and the fact that reducing incidence to the target in the risk areas will result in a  
196 subsequent reduction to even lower level of the national incidence [27]. We assumed that in  
197 those 25 countries VL burden supports the rationale for vaccine use. At-risk population data  
198 were retrieved at country level, where available, or at regional or global level [28][29][30].  
199 For each of those countries, only the portion of the population considered living in at-risk  
200 areas was included as target for the vaccination program. The upper limit of the size of the at-  
201 risk population was defined based on data from 13 WHO leishmaniasis country profiles [31]  
202 (data from 2014, 15 and 16 depending on the country) integrated with data from Pigott et al  
203 [28] that includes all geographical areas (at national or sub-national level) which could  
204 become endemic in the future. Additional validations were performed for the total population  
205 of the Indian subcontinent (India, Bangladesh and Nepal) [32]. The consolidated estimate for  
206 the 25 countries was allocated to the year 2014. The base case was centred around the latest  
207 available global WHO estimates of the overall population at risk of all leishmaniases (for  
208 2010) under the assumption that 100% of that population is at risk of VL. The assumption is

209 consistent with the analysis by Pigott et al [28] where the difference in size of VL and CL at-  
210 risk populations was minimal. The lower limit of the range was based on the 2009 global  
211 estimates developed by DNDi [30]. Since the year of reference was different for the different  
212 data sources, projections up to 2018 were built for each dataset, applying a population growth  
213 rate of 1.83%, corresponding to the 2010-2015 regional growths as reported by UN/DESA  
214 [33] and weighted based on regional VL cases from the GBD estimates 2019 for Asia  
215 inclusive of the Middle East, Africa and Latin America.

216  
217 *VL incidence.* Information for the 9 VL endemic countries relevant for PKDL was retrieved  
218 from the latest GBD 2019 [2] for the period 2010-2019. Other estimates of new VL cases  
219 were sourced from Alvar (personal communication) for India and East Africa for 2018 and  
220 from Mondal et al. [34] for India for the period 2005-2008.

221  
222 *PKDL prevalence.* Estimates of the rate of occurrence of sequelae of VL cases were used to  
223 define PKDL incidence. Different regional estimates were used for Asia [35] and Africa with  
224 high, low and medium points being defined. From the PKDL incidence , the 2016 PKDL  
225 estimated prevalence was derived considering an average 3.5 years duration of the lesions as  
226 indicated by Mondal [34].

227  
228 *Population at risk for CL.* 34 high-risk countries were selected, either those identified by  
229 WHO as high burden countries or those with an incidence above 5/100,000 according to the  
230 latest GBD estimates for 2019 [2] . For India, only 2 states with high endemicity (Rajasthan  
231 [36] and Kerala [37]) were included. Similar to VL, these countries and states were assumed  
232 to be those where CL burden supports the rationale for vaccine introduction. For each of  
233 those countries, only the portion of the population living in at-risk areas was included as a

234 target for the vaccination program. The upper limit of the size of the at-risk population was  
235 defined based on data from 12 WHO leishmaniasis country profiles [31] (data from 2014, 15  
236 and 16 depending on the country) and the consolidated regional 2014 estimate for the 12  
237 countries in the American region [38], integrated with data from Pigott et al. [28] from 2014.  
238 The consolidated estimate for the 34 countries was centred on the year 2014. The mid-point  
239 of the range was based on the global estimates from DNDi of the total cases of leishmaniasis  
240 [39], under the assumption that the countries included in the estimate were all at risk for CL.  
241 The lower limit of the range was based on the global WHO estimates for 2010 [29] of the  
242 overall population at risk of all leishmaniases under the assumption that 100% of these  
243 populations are at risk of CL. Similar to VL, projections up to 2018 were built applying a  
244 1.43% population growth rate for the period 2010-2015. This rate corresponds to the regional  
245 estimates as reported by UN/DESA[33] weighted based on the latest available regional CL  
246 cases from GBD 2019 for Asia inclusive of Middle-East, Africa and Latin America.

247  
248 The four estimates above were then projected through the year 2040 by using the weighted  
249 regional population growth rate (based on regional shares of the respective disease for the  
250 period 2019-2040 as estimated by the UN DESA[33]). Specifically, a growth rate of 1.80%  
251 was used for the population at risk of VL and 1.42% for the population at risk of CL. For the  
252 projection of the VL cases, a wave-shaped incidence curve was applied for the period 2017-  
253 2040 reflecting an epidemiological trend with 5 years of decline followed by 5 years of  
254 growth, but less accentuated than the cyclical incidence variations induced by El Niño [40]  
255 [41] [42], and using the UN DESA regional average annual growth rates for the period 2010-  
256 2016 (with a positive sign in the growth and a negative sign in the decline years).

257

258 **Modelling the targeted population**

259 *Adoption sequence in the targeted countries.* The adoption curve indicates the growing  
260 proportion of the targeted population that can be reached with the vaccine as result of country  
261 introduction decisions. Country adoption decisions are often guided by an assessment of the  
262 benefits of vaccination under different conditions by the National Immunisation Technical  
263 Advisory Group (NITAG) based on the country and region-specific context. The likelihood  
264 of NITAG recommendations for vaccine introduction in different countries was accounted for  
265 by including only high-risk countries based on incidence thresholds as indicated earlier .  
266 In contrast to prophylactic vaccines, preventative and therapeutic vaccines do not have the  
267 same requirement for centralized decision-making. The countries where PKDL is endemic  
268 are thus assumed as introducing the vaccine.

269

270 In view of the early state of development, interest of individual countries for introduction of a  
271 leishmaniasis vaccines cannot easily be assessed, hence a proxy was identified to define the  
272 sequence of adoption in the selected countries. Since 21 of the 25 countries (84%) which are  
273 likely targets for the introduction of a VL vaccine and 13 of the 34 countries (38%) which are  
274 likely targets for a CL vaccine are or were eligible for Gavi support, the sequence of  
275 introduction in the Gavi countries for Pneumococcal Conjugate Vaccine [43] was selected as  
276 the most meaningful proxy.

277

278 *Impact of vaccine introduction on target populations.* The introduction of a leishmaniasis  
279 vaccine that triggers an effective host protective immune response will decrease the size of  
280 the population at risk. We assumed that the introduction of a VL prophylactic vaccine would  
281 decrease populations at risk and also reduce transmission in areas with exclusive  
282 anthroponotic transmission (South Sudan, Sudan, Somalia, India, Nepal, Bangladesh and the  
283 Xinjiang region in China). In those countries, it was assumed that the decline of the

284 population at risk would take place linearly and that immunisation would progressively be  
285 stopped once all blocks or districts have reached a VL elimination target of less than 1 VL  
286 case per 10,000 per year. This is estimated starting from the sixth year after vaccine  
287 introduction, spreading over a period 4 years. In areas where VL transmission is zoonotic,  
288 vaccination is assumed to continue unchanged. In a similar fashion, we assumed that a CL  
289 prophylactic vaccine, while protecting individuals, will have less impact on transmission  
290 given the zoonotic nature of this disease, hence immunization will not be stopped in any CL  
291 at-risk area. Finally, the impact of a VL prophylactic vaccine on VL incidence and thus,  
292 indirectly, also on the size of the target population for the prevention of PKDL was estimated  
293 referring to recent disease transmission modelling work for India, where anthroponotic  
294 transmission was assumed [44] (29). In that model (under the assumption that asymptomatic  
295 individuals also contribute to VL transmission), the reduction in the number of cases  
296 following prophylactic vaccination with a 50% efficacious vaccine covering 100% of the  
297 population was estimated to be 30%, 50% and 62% in years 1, 2 and 3 following the  
298 introduction of the vaccine [44].

299  
300 The impact of a PKDL preventative vaccine on PKDL incidence was modeled taking into  
301 account the following factors: i) the year of introduction of the vaccine, ii) the proportion of  
302 the total population reached as a result of a vaccine deployment spread out over 2 years, and  
303 iii) the estimated reduction of VL cases. As a result, a 50% reduction in year 2 and a 90%  
304 reduction from year 3 onward is used to estimate the reduction in the number of cases in each  
305 of the 3 scenarios with year 1 being the year of introduction of the vaccine.

306

307 For the impact of a PKDL therapeutic vaccine on PKDL incidence, no changes to the target  
308 population were assumed.

309

## 310 **Modelling the demand for a leishmaniasis vaccine**

311 With the target population estimates established and expected changes to the size of those  
312 populations modelled, we subsequently defined a number of assumptions related to the  
313 vaccination program and to the vaccine characteristics.

314

315 *Date of registration of the vaccine.* Based on the current status of vaccines in clinical  
316 development, we took the earliest year of first registration for both VL and CL preventative  
317 vaccines as 2029. We then assumed 12 months for obtaining WHO prequalification (PQ) to  
318 allow procurement through the United Nations system. The PQ date is based on the  
319 assumption that the vaccine will be developed by an experienced manufacturer and is  
320 consistent with assumptions used by the WHO in similar analyses [45]. Thus, 2030 was  
321 assumed as the year of start of a phased global roll-out for both indications. A PKDL  
322 therapeutic vaccine (ChAd63-KH) is in Phase IIb therapeutic trial in in Sudan [46] while  
323 Phase II trials of the same vaccine to prevent PKDL in previously treated VL patients may  
324 begin in 2021. Should one or both of these approaches prove successful, such a vaccine might  
325 progress through other trials to allow registration in 2027.

326

327 *Vaccine characteristics and immunisation schedule:* For estimating the demand, key vaccine  
328 product characteristics were assumed. Target product profile (TPP) assumptions relevant to  
329 the calculation of a demand forecast are shown in **Table 4**. Of special importance is the  
330 assumption of cross-protection of a vaccine against visceral and cutaneous leishmaniasis, as  
331 suggested by studies with different *Leishmania* species in experimental models [47] [48].  
332 Assumptions regarding the duration of protection and number of vaccination series (the  
333 number of times a person undergoes one full vaccination cycle) were made based on historic

334 evidence, regulatory assumptions and practical considerations. A minimum of five years  
335 duration of protection was assumed based on the consideration that a shorter duration would  
336 likely render the vaccine too cumbersome for implementation and too expensive for use in  
337 view of the number of doses required to maintain protection for the first 15 years of life (e.g.,  
338 the age groups with the highest disease burden). In addition, key assumptions were made  
339 regarding the immunisation schedule, including broad age-range catch-up campaigns at start  
340 of the vaccine roll-out in each country with the goal of reducing susceptible unprotected  
341 populations in an efficient and timely manner. To capture a main area of uncertainty, a  
342 second more conservative scenario has been run simulating a first priming dose followed by  
343 1 booster dose after 5 years and a second booster after 10 years for a total of 3 doses (instead  
344 of the 6 of the base case).

345

346 *Vaccine coverage.* The maximum achievable coverage was estimated for different vaccine  
347 schedules based on coverage achieved in routine vaccination in the same age groups [49] [50]  
348 or coverage achieved in campaigns in the relevant regions [51](**Table 5**).

349 As a simplifying assumption, the time required to achieve the full coverage within each  
350 country was set at 12 months.

351

352 A detailed review of the calculations is available in **Supplementary Text File**.

353

## 354 **Results**

### 355 **Determination of use cases**

356 Eleven use cases emerged as a result of the review (**Table 1**). Three of these use cases were  
357 deprioritised in view of their limited size and impact on the total demand. For each of the  
358 remaining eight use cases, the most appropriate delivery strategy was defined according to

359 the target geography and goal (prophylaxis, prevention or treatment). Due to the focal  
360 distribution of leishmaniasis and the high population mobility in most of the endemic areas,  
361 delivery strategies were assumed to focus on at-risk populations rather than at-risk areas. In  
362 finalising the use cases, the following two aspects were also considered: (a) a CL therapeutic  
363 vaccine will target a subset of the population also targeted by the CL prophylactic vaccine  
364 (the population at risk of CL); (b) vaccine development efforts will most likely not focus on  
365 geographically limited indications. As result of those considerations, the eight prioritised use  
366 cases were further consolidated into four by eliminating the differentiation by geography and  
367 co-morbidity for the CL use cases (**Table 2**). These four use cases and the related delivery  
368 strategies provide the foundation for the assessment of the size of the demand for  
369 leishmaniasis vaccines given the different indications.

370

### 371 **Target population estimates**

372 Using a variety of source data (see Methods), we generated upper and lower limits of target  
373 populations that are at risk of developing VL or CL and who might therefore benefit from a  
374 prophylactic vaccine. Similarly, upper and lower limits are estimated for preventative and  
375 therapeutic vaccines for PKDL. In addition, we identified a base case or central-point  
376 estimate of the population at risk (**Table 3**). For both VL and CL prevention, the 2018  
377 estimates of populations at risk ranged from 647 million to 235 million for VL and from 1  
378 billion to 392 million for CL. Based on the assumption of cross-protectivity and taking into  
379 account the population of the 4 countries<sup>3</sup> included in the analysis that are endemic for both  
380 manifestation of the disease, approximately 29% of the population at risk of CL is considered  
381 also at risk of VL and was therefore deducted from the calculation of the CL target

---

<sup>3</sup> Brazil, India, Paraguay and Sudan



382 population. Estimates for the prevention of PKDL ranged from 31,892 to 12,635 and for  
383 treatment of PKDL from 6,141 to 2,460, emphasizing a marked difference in scale for these  
384 different indications.

385

### 386 **Potential demand estimates for VL and CL prophylactic vaccines.**

387 Based on the above assumptions, we calculate that peak combined potential demand for VL  
388 and CL would be approximately 190 million doses in 2033 (of which approximately 1/3 are  
389 for VL) (**Figure 2**). Demand shows a variable profile as a result of the impact of the large  
390 catch-up campaigns aimed at multiple age cohorts (10 cohorts for VL and 25 cohorts for CL):  
391 as the population covered by the initial catch-up campaigns grows older, the portion of the 0-  
392 15 age group requiring boosting via routine immunization will grow. After 2034, the  
393 increasing impact of the vaccine will result in the progressive reduction in size of the VL at-  
394 risk population offsetting the additional populations introducing the vaccine. As a  
395 consequence, demand is predicted to decline progressively until 2038, reflecting the  
396 elimination [52] of VL in the Indian subcontinent<sup>4</sup>, and thereafter to stabilise at around 160  
397 million doses per year across the two indications.

398

399 Estimates in single years are a function of many variables and may have limited predictive  
400 value and the portion of demand that will be served would most likely be capped at some  
401 level due to limits of manufacturing capacity. The cumulative number of doses over the 11  
402 years between 2030 and 2040 is thought to provide a reasonable and relevant estimate  
403 resulting in a demand for approximately 1.6 billion doses across the 2 disease states

---

<sup>4</sup> Such an assumption, based on the historical trend of the last decade requires continued investment in surveillance and introduction of better diagnostic methods [62]

404 (approximately 500 million for VL and 1.1 billion for CL) or an average of 145 million doses  
405 per year. It is important to note that this estimate is significantly impacted by the assumption  
406 that six doses will be required for each person vaccinated. In the more conservative scenario  
407 where only 3 doses are required, those numbers are reduced by half (800 million doses over  
408 the 11 years across the 2 disease states).

409

410 Of interest is the split between campaigns (for catch-up vaccination at start) and routine use,  
411 with the former being more volatile and dependent on the number of cohorts targeted and the  
412 timing of catch-up campaigns in different countries. It is estimated that 39% of the doses  
413 (approximately 615 million doses) will be used in campaigns to reach 5-14 year olds for  
414 protection against VL and 5-29 year olds for protection against CL in view of the different  
415 age distribution of the disease [53] while the remaining 61% (approximately 980 million  
416 doses) will be used in routine immunisation in areas with high CL prevalence (because of the  
417 larger and stable population reached) (**Figure 3**).

418

419 Two additional simulations were also performed. One simulation used the lower population  
420 scenario as a way of reflecting a conservative block-focused immunization strategy and a  
421 significant negative impact of vaccine hesitancy. A second simulation used the higher  
422 population scenario so as to capture a more extensive definition of risk-areas and also  
423 incorporating a broader impact of climate change on the spread of the disease. The first  
424 scenario was reflected in a reduction of the total doses over the 11 years from 1.6 billion to  
425 858 million (301 million for VL and 557 million for CL); the second scenario resulted instead  
426 in an increase to 2.2 billion doses over the 11 years (830 million for VL and 1.4 billion for  
427 CL).

428

## 429 **Potential demand estimates for PKDL targeted vaccines.**

430 Assuming implementation of an effective VL prophylactic vaccine, total PKDL demand will  
431 peak at 27,300 doses in 2028 with approximately 90% of demand for preventive use (**Figure**  
432 **4**). For therapeutic use, demand is estimated at 3300 doses in 2027 (at the time of vaccine  
433 introduction) declining to less than one hundred doses by 2036. Overall demand will further  
434 decline to less than 1,000 doses in 2039 as result of the cumulative impact of preventative  
435 vaccine use, compounded by the reduction in VL cases driven by the introduction of the VL  
436 prophylactic indication. The total demand for a PKDL therapeutic vaccine over the 13 years  
437 will be 7,200 doses, while the total demand for a vaccine to prevent PKDL over the same  
438 period will be 161,000 doses. Of interest is the scenario where a stand-alone therapeutic /  
439 preventative vaccine for PKDL is developed in the absence of an effective prophylactic  
440 vaccine for VL and hence with no vaccine-related reduction in VL cases. Under those  
441 circumstances, the total potential demand for a PKDL vaccine doubles to more than 330,000  
442 doses over the period.

443

## 444 **Discussion**

445 In order to fully ascertain the potential interest of developers for a program aimed at  
446 developing a vaccine against leishmaniasis, we conducted an in-depth analysis of the  
447 potential global demand for leishmaniasis vaccines that is generally agnostic to the nature of  
448 the vaccine.

449

450 The assessment of the use cases for leishmaniasis vaccines emphasizes four main indications:  
451 two for the prevention of VL and CL respectively, and two for the prevention and treatment  
452 of PKDL. In endemic countries, those vaccines will reduce cases of disease and decrease  
453 community transmission. Based on the estimates of the populations at risk and the

454 consequent demand, prophylactic VL and CL vaccine indications are the most attractive  
455 scenarios both from a public health and commercial standpoint. A vaccine that is cross-  
456 protective against VL and CL has the strongest value proposition, whilst only one indication  
457 still allows for a significant demand size and public health impact. PKDL indications also  
458 retain their importance from a public health standpoint or in view of existing progress in  
459 clinical development that may lead to the earlier availability of this vaccine.

460

461 Availability of a vaccine for one or more of these indications will provide an opportunity to  
462 reduce the threat of leishmaniasis as a public health problem in 57 countries<sup>5</sup>. This includes  
463 22 countries in the African continent, 14 in the Americas, 19 in Asia, and 2 in the European  
464 region. At the same time 3 of these countries are High-Income (HICs), 18 Upper Middle-  
465 income (UMICs), 19 Lower-Middle-Income (LMICs) and 15 Low-income (LICs) [54] as  
466 defined by the World Bank income classification. Of the latter two groups, 22 countries are,  
467 and 10 have previously been, eligible for Gavi support including funding for vaccine  
468 procurement. It is assumed that HICs or UMICs would potentially be able to self-finance,  
469 while LMICs and LICs could benefit from the financial support of Gavi and other donors.

470

471 The total population potentially targeted by leishmaniasis vaccines approximates 1.1 billion  
472 in 2030 by the time of introduction of the vaccine. On the basis of data from 2018, the  
473 population at risk of VL (404 million with a range between 235 and 646 million) and at risk  
474 of CL (765 million with a range between 392 million and 1 billion) represents the near  
475 totality of the potential target for the vaccine while the numbers of VL cases in the targeted  
476 countries (16,129 new cases per year for 2030 with a range between 2,843 and 25,068 cases)

---

<sup>5</sup> The 57 countries are split as follow: India and Sudan, for the 3 manifestations of the disease, 4 countries for VL and CL, 7 countries for VL and PKDL, 14 countries for VL only, and 30 countries for CL only

477 and of PKDL (3,104 new cases per year for 2030 in absence of a vaccine, with a range  
478 between 600 and 4,752 cases) are much more limited. It is evident that vaccine use in such  
479 large populations could result in significant public health benefits.

480

481 The vaccine supply required over 10 years (2030-2040) for the implementation of  
482 immunisation programs against VL or CL could be substantial: approximately 1.1 billion  
483 doses of vaccine against CL (range: 0.5 – 1.4 billion doses) and 0.5 billion doses of vaccine  
484 against VL (range: ~ 0.3 – 0.8 billion doses). Markets of this size have the potential to attract  
485 the interest of vaccine manufacturers, even more so in view of the mix of economies  
486 involved, some of which may self-finance a respective immunization program. For this  
487 interest to materialise, utmost transparency will be necessary on the countries' willingness  
488 and ability to pay for the vaccines, as well as clarity on WHO recommendations for vaccine  
489 use. Establishment of incentive mechanisms, such as Advanced Market Commitments [55]  
490 and Priority Review Vouchers [56], can also play an important incentivizing role. This will  
491 be critical for supporting the progress of current vaccine development efforts.

492

493 It is not yet established whether a vaccine that prevents clinical VL will also prevent the  
494 development of PKDL. If this were not the case, making available a vaccine that is selective  
495 for PKDL may be more challenging in view of the more limited potential demand. However,  
496 a different approach may be pursued for this indication leveraging the limited demand as an  
497 opportunity instead of a constraint. Regulatory frameworks for orphan or compassionate use  
498 indications could be exploited and combined with limited manufacturing needs and  
499 investments, reducing greatly the cost and the risk for a manufacturer. Such a focused  
500 approach to vaccine financing should be explored to address the burden of PKDL.

501

502 To support countries in their assessment of the public health impact of a leishmaniasis  
503 vaccine and prospective manufacturers of the commercial value proposition of those  
504 vaccines, clarity on target populations and demand is paramount. The Hib Initiative, as well  
505 as the Pneumococcal and Rotavirus Vaccine Accelerated Development and Introduction  
506 Plans (PneumoADIP and RotaADIP) provide examples on how a concurrent effort on data  
507 generation, clinical development and public advocacy was able to raise awareness on diseases  
508 with a heavy burden on populations of LMICs and LICs [57]. Such an approach is even more  
509 critical for neglected tropical diseases such as leishmaniasis.

510

511 The limitations of this analysis, as for any forecasting exercise, relate to various elements of  
512 uncertainty. Firstly, the forecast is dependent on the estimates of the at-risk populations in  
513 endemic or potentially endemic areas as well as on the assumed future incidence and  
514 prevalence of the disease. With current leishmaniasis control programmes in place in certain  
515 parts of the world, such incidence will depend on the success of these programmes. There is  
516 no clear consensus among experts and estimates show a high degree of variability while an  
517 agreed definition of the target population at risk, by countries or sub populations of countries,  
518 is missing. Secondly, assumptions concerning the probability of country vaccine introduction  
519 are subject to a high degree of uncertainty given that vaccines will likely not be available for  
520 another decade. Thirdly, the estimate of the impact of the use of vaccines in the target  
521 populations is based on a set of assumptions while awaiting the outcomes of vaccine trials  
522 Work done by Erasmus MC (University Medical Center, Rotterdam) provides information on  
523 the potential impact of various VL vaccines on VL incidence in an Indian setting [44], but not  
524 elsewhere. Whilst our modelling assumptions include transmission by asymptomatic cases of  
525 VL, a recent study from India suggests that this may be more limited than previously thought  
526 [58] . Studies of transmission competence across the disease spectrum in other regions where

527 VL is endemic are clearly warranted. Additional simulations of the impact of vaccines in CL  
528 and VL populations at risk (including the likelihood of interruption of transmission and of the  
529 impact of a VL prophylactic vaccine), will further improve our understanding of population  
530 dynamics and vaccine effectiveness. Finally, a number of initial assumptions were made on  
531 variables such as the sequence of country introduction, vaccine uptake, achievable and  
532 desired coverage and vaccination schedules. Changes in these parameters and the priority  
533 countries introducing the vaccines will impact the forecasted demand. As an example, the  
534 impact of a different immunisation schedule, as captured in the conservative scenario  
535 described in the results section (with a reduced series of 3 doses instead of 6), has the  
536 potential to reduce demand by up to 50%. Getting closer to registration, more precise  
537 information about vaccine product characteristics, and the likely program designs and  
538 country interest will allow for more refined estimates.

539

540 In conclusion, there is a growing consensus on the need for a vaccine against leishmaniasis to  
541 achieve a reduction of the burden of disease [59][60][61]. Clarity about the prospective size  
542 of the vaccine demand in terms of target population and number of doses required is crucial  
543 to inform decisions of manufacturers, donors and countries. Our first-of-a-kind analysis  
544 provides a global estimate of the potential demand for leishmaniasis vaccines across a set of  
545 different indications. Subject to prioritization of country and global decision makers, a  
546 leishmaniasis vaccine with a VL and/or CL indication could not only provide a significant  
547 contribution to the reduction of the burden of NTDs but also has the potential of being an  
548 interesting commercial prospect for vaccine developers. Further analyses to confirm the  
549 likelihood and strength of interest of country decision makers in prioritising leishmaniasis  
550 vaccines in their adoption decisions are warranted. This will enable further clarification on  
551 the potential reduction in the burden of the disease and cost-effectiveness of these vaccines.

552

553

## 554 **Acknowledgments**

555 The authors of this article wish to thank the members of the expert group who provided  
556 insights and guidance in the development of the use cases and who critically reviewed the  
557 manuscript. In particular, we thank Jorge Alvar, Simon Croft, Nirmal Kumar Ganguly and  
558 Greg Matlashewski who dedicated time to validate some of our assumptions. Finally, we are  
559 grateful to the Wellcome Trust for supporting expert meetings during the project timeline and  
560 allowing for additional fruitful interactions.

561

## 562 **Funding**

563 This work was funded by a Translation Award from the Wellcome Trust (Grant No. 108518;  
564 to PMK). The funder had no role in the design or execution of the study or the decision to  
565 publish. EALR gratefully acknowledges funding of the NTD Modelling Consortium by the  
566 Bill and Melinda Gates Foundation (OPP1184344).

567

## 568 **Conflict of interest statement**

569 PMK is co-author of a patent protecting the gene insert used in *Leishmania* candidate vaccine  
570 ChAd63-KH (Europe 10719953.1; India 315101) and is funded by the UK Medical Research  
571 Council / Department for International Development to develop a controlled human infection  
572 model for sand fly-transmitted cutaneous leishmaniasis. MMGH Consulting were appointed  
573 to lead the work under contract from the University of York.

574

575



## 576 **References**

- 577 1. Hotez PJ. The global fight to develop antipoverty vaccines in the anti-vaccine era.  
578 Hum Vaccines Immunother. 2018;14: 2128–2131.  
579 doi:10.1080/21645515.2018.1430542
- 580 2. Abbafati C, Machado DB, Cislighi B, Salman OM, Karanikolos M, McKee M, et al.  
581 Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019:  
582 a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:  
583 1204–1222. doi:10.1016/S0140-6736(20)30925-9
- 584 3. Kaslow DC, Black S, Bloom DE, Datla M, Salisbury D, Rappuoli R. Vaccine  
585 candidates for poor nations are going to waste. Nature. 2018. doi:10.1038/d41586-018-  
586 07758-3
- 587 4. Bottazzi ME, Hotez PJ. “Running the Gauntlet”: Formidable challenges in advancing  
588 neglected tropical diseases vaccines from development through licensure, and a “Call  
589 to Action.” Hum Vaccines Immunother. 2019;15: 2235–2242.  
590 doi:10.1080/21645515.2019.1629254
- 591 5. MMGH. Effective Vaccine Ecosystem, - a reaserch project for the Wellcome Trust.  
592 2020.
- 593 6. World Health Organization. Key Facts - Leishmaniasis. In: WHO Website [Internet].  
594 2020 [cited 20 Feb 2020]. Available: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/leishmaniasis)  
595 [sheets/detail/leishmaniasis](https://www.who.int/news-room/fact-sheets/detail/leishmaniasis)
- 596 7. Chakravarty J, Sundar S. Current and emerging medications for the treatment of  
597 leishmaniasis. Expert Opinion on Pharmacotherapy. 2019.  
598 doi:10.1080/14656566.2019.1609940
- 599 8. Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, et al. Recent  
600 development of visceral leishmaniasis treatments: Successes, pitfalls, and perspectives.  
601 Clinical Microbiology Reviews. 2018. doi:10.1128/cmr.00048-18
- 602 9. Molina R, Ghosh D, Carrillo E, Monnerat S, Bern C, Mondal Di, et al. Infectivity of  
603 Post-Kala-azar Dermal Leishmaniasis Patients to Sand Flies: Revisiting a Proof of  
604 Concept in the Context of the Kala-azar Elimination Program in the Indian  
605 Subcontinent. Clin Infect Dis. 2017;65: 150–153. doi:10.1093/cid/cix245
- 606 10. Singh OP, Tiwary P, Kushwaha AK, Singh SK, Singh DK, Lawyer P, et al.  
607 Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area  
608 endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. The

- 609 Lancet Microbe. 2021. doi:10.1016/s2666-5247(20)30166-x
- 610 11. Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M. Post kala-azar dermal  
611 leishmaniasis: An unresolved mystery. *Trends Parasitol.* 2014;30: 65–74.  
612 doi:10.1016/j.pt.2013.12.004
- 613 12. Le Rutte EA, Zijlstra EE, de Vlas SJ. Post-Kala-Azar Dermal Leishmaniasis as a  
614 Reservoir for Visceral Leishmaniasis Transmission. *Trends in Parasitology.* 2019.  
615 doi:10.1016/j.pt.2019.06.007
- 616 13. Bailey F, Mondragon-Shem K, Hotez P, Ruiz-Postigo JA, Al-Salem W, Acosta-  
617 Serrano Á, et al. A new perspective on cutaneous leishmaniasis—Implications for  
618 global prevalence and burden of disease estimates. *PLoS Negl Trop Dis.* 2017;11: 2–6.  
619 doi:10.1371/journal.pntd.0005739
- 620 14. Nassif PW, De Mello TFP, Navasconi TR, Mota CA, Demarchi IG, Aristides SMA, et  
621 al. Safety and efficacy of current alternatives in the topical treatment of cutaneous  
622 leishmaniasis: A systematic review. *Parasitology.* 2017;144: 995–1004.  
623 doi:10.1017/S0031182017000385
- 624 15. Pinart M, Jr R, Gas R, Ce P, An SM, Reveiz L, et al. Pinart M, Rueda JR, Romero  
625 GAS, Pinzón-Flórez CE, Osorio-Arango K, Silveira Maia-Elkhoury AN, Reveiz L,  
626 Elias VM, Tweed JA. 2020.  
627 doi:10.1002/14651858.CD004834.pub3.www.cochranelibrary.com
- 628 16. Melby PC. Experimental Leishmaniasis in Humans: Review. *Rev Infect Dis.* 1991;13:  
629 1009–1017. doi:10.1093/clinids/13.5.1009
- 630 17. Scott P, Novais FO. Cutaneous leishmaniasis: Immune responses in protection and  
631 pathogenesis. *Nature Reviews Immunology.* 2016. doi:10.1038/nri.2016.72
- 632 18. Cecílio P, Oliveira F, Silva AC da. Vaccines for Human Leishmaniasis: Where Do We  
633 Stand and What Is Still Missing? *Leishmaniases as Re-emerging Diseases.* InTech;  
634 2018. pp. 59–79. doi:10.5772/intechopen.75000
- 635 19. Moafi M, Sherkat R, Taleban R, Rezvan H. Leishmania vaccines entered in clinical  
636 trials: A review of literature. *International Journal of Preventive Medicine.* 2019.  
637 doi:10.4103/ijpvm.IJPVM\_116\_18
- 638 20. Zhang WW, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, et al. A  
639 second generation leishmanization vaccine with a markerless attenuated *Leishmania*  
640 major strain using CRISPR gene editing. *Nat Commun.* 2020;11: 1–14.  
641 doi:10.1038/s41467-020-17154-z

- 642 21. Srivastava S, Shankar P, Mishra J, Singh S. Possibilities and challenges for developing  
643 a successful vaccine for leishmaniasis. *Parasites and Vectors*. 2016;9: 1–15.  
644 doi:10.1186/s13071-016-1553-y
- 645 22. Ashwin H, Sadlova J, Vojtkova B, Becvar T, Lypaczewski P, Schwartz E, et al.  
646 Characterization of a new *Leishmania major* strain for use in a controlled human  
647 infection model. *Nat Commun*. 2021. doi:10.1038/s41467-020-20569-3
- 648 23. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis  
649 worldwide and global estimates of its incidence. *PLoS One*. 2012;7.  
650 doi:10.1371/journal.pone.0035671
- 651 24. Zuber PLF, Dumolard L, Shirey M, Rizzo I, Marshall J. Forecasting demand for Hib-  
652 containing vaccine in the world's poorest countries: A 4-year prospective experience.  
653 *Vaccine*. 2009;27: 410–415. doi:10.1016/j.vaccine.2008.10.069
- 654 25. Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue  
655 vaccine demand in disease endemic and non-endemic countries. *Hum Vaccin*. 2010;6:  
656 745–753. doi:10.4161/hv.6.9.12587
- 657 26. Cernuschi T, Malvolti S, Nickels E, Friede M. Bacillus Calmette-Guérin (BCG)  
658 vaccine: A global assessment of demand and supply balance. *Vaccine*. 2018;36.  
659 doi:10.1016/j.vaccine.2017.12.010
- 660 27. Jervis S, Chapman LAC, Dwivedi S, Karthick M, Das A, Le Rutte EA, et al.  
661 Variations in visceral leishmaniasis burden, mortality and the pathway to care within  
662 Bihar, India. *Parasit Vectors*. 2017. doi:10.1186/s13071-017-2530-9
- 663 28. Pigott DM, Sumiko Mekaru HR, Gething PW, George DB, Myers MF, Reithinger R,  
664 et al. Global Distribution Maps of the Leishmaniasis. *Elife*. 2014;2010: 1–21.  
665 doi:10.7554/eLife.02851
- 666 29. World Health Organization. Control of the leishmaniasis. *World Health Organ Tech*  
667 *Rep Ser*. 2010; 22–26.
- 668 30. Drug for Neglected Disease Initiative. DNDi - NewsLetter. [cited 2 Jan 2020].  
669 Available: [https://www.dndi.org/newsletters/n18/4\\_1.php](https://www.dndi.org/newsletters/n18/4_1.php)
- 670 31. World Health Organization. WHO | New leishmaniasis country profiles based on  
671 routine surveillance data. [cited 2 Jan 2020]. Available:  
672 [https://www.who.int/neglected\\_diseases/news/New\\_leishmaniasis\\_country\\_profiles\\_b](https://www.who.int/neglected_diseases/news/New_leishmaniasis_country_profiles_based_on_routine_surveillanc/en/)  
673 [ased\\_on\\_routine\\_surveillanc/en/](https://www.who.int/neglected_diseases/news/New_leishmaniasis_country_profiles_based_on_routine_surveillanc/en/)
- 674 32. Karunaweera ND, Ferreira MU. Leishmaniasis: Current challenges and prospects for

- 675 elimination with special focus on the South Asian region. *Parasitology*. 2018;145:  
676 425–429. doi:10.1017/S0031182018000471
- 677 33. United Nations - Department for Economic and Social Affairs. World Population  
678 Prospects - Population Division - United Nations. In: World Population Prospects  
679 2019 [Internet]. [cited 2 Jan 2020]. Available:  
680 <https://population.un.org/wpp/Download/Standard/Population/>
- 681 34. Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, et al. Quantifying  
682 the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies. *Clin Infect*  
683 *Dis*. 2019;69: 251–258. doi:10.1093/cid/ciy891
- 684 35. Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J. Post-kala-azar dermal leishmaniasis in  
685 the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination  
686 Programme. *PLoS Neglected Tropical Diseases*. 2017.  
687 doi:10.1371/journal.pntd.0005877
- 688 36. Aara N, Khandelwal K, Bumb RA, Mehta RD, Ghiya BC, Jakhar R, et al. Clinico-  
689 epidemiologic study of cutaneous leishmaniasis in bikaner, Rajasthan, India. *Am J*  
690 *Trop Med Hyg*. 2013. doi:10.4269/ajtmh.12-0558
- 691 37. Simi S, Anish T, Jyothi R, Vijayakumar K, Philip R, Paul N. Searching for cutaneous  
692 leishmaniasis in tribals from Kerala, India. *J Glob Infect Dis*. 2010. doi:10.4103/0974-  
693 777x.62874
- 694 38. PAHO. Leishmaniasis - Epidemiological Report of the Americas - N°4. 2016.
- 695 39. Drug for Neglected Disease Initiative. About Leishmaniasis – DNDi. 2019 [cited 31  
696 Dec 2019]. Available: <https://www.dndi.org/diseases-projects/leishmaniasis/>
- 697 40. Leta S, Dao THT, Mesele F, Alemayehu G. Visceral Leishmaniasis in Ethiopia: An  
698 Evolving Disease. *PLoS Negl Trop Dis*. 2014. doi:10.1371/journal.pntd.0003131
- 699 41. Neto AB da S, de Oliveira EF, Encina CCC, de Figueiredo HR, Filho ACP, de  
700 Oliveira AG. Effects of El Niño-Southern oscillation on human visceral leishmaniasis  
701 in the Brazilian State of Mato Grosso do Sul. *Mem Inst Oswaldo Cruz*. 2020;115: 1–8.  
702 doi:10.1590/0074-02760190298
- 703 42. Deb RM, Stanton MC, Foster GM, Das Gupta RK, Roy N, Das P, et al. Visceral  
704 leishmaniasis cyclical trends in Bihar, India – Implications for the elimination  
705 programme. *Gates Open Res*. 2018. doi:10.12688/gatesopenres.12793.1
- 706 43. Johns Hopkins Bloomberg School of Public Health International Vaccine Access  
707 Center (IVAC). A report on current global access to new childhood vaccines. 2019.

- 708 44. Le Rutte EA, Coffeng LE, Malvolti S, Kaye PM, de Vlas SJ. The potential impact of  
709 human visceral leishmaniasis vaccines on population incidence. *PLoS Negl Trop Dis*.  
710 2020;14: 1–13. doi:10.1371/journal.pntd.0008468
- 711 45. World Health Organization. MI4A - Market Information for Access to Vaccines. 2020.
- 712 46. Younis B, Osman M, Khalil E, Santoro F, Furini S, Wiggins R, et al. Safety and  
713 immunogenicity of ChAd63-KH vaccine in post kala azar dermal leishmaniasis  
714 patients in Sudan. *medRxiv*. 2020; 2020.08.26.20180901.  
715 doi:10.1101/2020.08.26.20180901
- 716 47. Romano A, Doria NA, Mendez J, Sacks DL, Peters NC. Cutaneous Infection with  
717 *Leishmania major* Mediates Heterologous Protection against Visceral Infection with  
718 *Leishmania infantum*. *J Immunol*. 2015. doi:10.4049/jimmunol.1500752
- 719 48. Ramirez L, Corvo L, Duarte MC, Chávez-Fumagalli MA, Valadares DG, Santos DM,  
720 et al. Cross-protective effect of a combined L5 plus L3 *Leishmania major* ribosomal  
721 protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral  
722 leishmaniasis. *Parasites and Vectors*. 2014;7: 1–11. doi:10.1186/1756-3305-7-3
- 723 49. World Health Organization. Immunization Coverage. In: World Health Data Platform.  
724 2020.
- 725 50. Hinman AR, Helms CM, Arvin AM, Freed GL, Guerra FA, Johnson DR, et al.  
726 Financing vaccines in the 21st century: Recommendations from the National Vaccine  
727 Advisory Committee. *American Journal of Preventive Medicine*. 2005.  
728 doi:10.1016/j.amepre.2005.03.005
- 729 51. World Health Organization. Summary Measles SIA 2000-2020. 2020.
- 730 52. Rijal S, Sundar S, Mondal D, Das P, Alvar J, Boelaert M. Eliminating visceral  
731 leishmaniasis in South Asia: The road ahead. *BMJ (Online)*. 2019.  
732 doi:10.1136/bmj.k5224
- 733 53. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global,  
734 regional, and national incidence, prevalence, and years lived with disability for 354  
735 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic  
736 analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018.  
737 doi:10.1016/S0140-6736(18)32279-7
- 738 54. World Bank. World Bank Country and Lending Groups – World Bank Data Help  
739 Desk. In: Country classification [Internet]. [cited 3 Jan 2020]. Available:  
740 <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank->

- 741 country-and-lending-groups
- 742 55. Snyder CM, Begor W, Berndt ER. Economic perspectives on the advance market  
743 commitment for pneumococcal vaccines. *Health Aff.* 2011;30: 1508–1517.  
744 doi:10.1377/hlthaff.2011.0403
- 745 56. Olliaro PL, Kuesel AC, Halleux CM, Sullivan M, Reeder JC. Creative use of the  
746 priority review voucher by public and not-for-profit actors delivers the first new FDA-  
747 approved treatment for river blindness in 20 years. *PLoS Negl Trop Dis.* 2018;12: 10–  
748 13. doi:10.1371/journal.pntd.0006837
- 749 57. Jamka LP, Simiyu KW, Bentsi-Enchill AD, Mwisongo AJ, Matzger H, Marfin AA, et  
750 al. Accelerating typhoid conjugate vaccine introduction: What can be learned from  
751 prior new vaccine introduction initiatives? *Clin Infect Dis.* 2019.  
752 doi:10.1093/cid/ciy1118
- 753 58. Singh OP, Tiwary P, Kushwaha AK, Singh SK, Singh DK, Lawyer P, et al.  
754 Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area  
755 endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. *The*  
756 *Lancet Microbe.* 2021;2: e23–e31. doi:10.1016/s2666-5247(20)30166-x
- 757 59. Mo AX, Pesce J, Fenton Hall B. Meeting report: Visceral leishmaniasis control and  
758 elimination: Is there a role for vaccines in achieving regional and global goals? *Am J*  
759 *Trop Med Hyg.* 2016;95: 514–521. doi:10.4269/ajtmh.16-0184
- 760 60. Engwerda CR, Matlashewski G. Development of *Leishmania* vaccines in the era of  
761 visceral leishmaniasis elimination. *Trans R Soc Trop Med Hyg.* 2015;109: 423–424.  
762 doi:10.1093/trstmh/trv039
- 763 61. Matlashewski G, Arana B, Kroeger A, Be-Nazir A, Mondal D, Nabi SG, et al.  
764 Research priorities for elimination of visceral leishmaniasis. *Lancet Glob Heal.*  
765 2014;2: e683–e684. doi:10.1016/S2214-109X(14)70318-3
- 766 62. Sundar S, Singh OP, Chakravarty J. Visceral leishmaniasis elimination targets in India,  
767 strategies for preventing resurgence. *Expert Review of Anti-Infective Therapy.* 2018.  
768 doi:10.1080/14787210.2018.1532790
- 769
- 770

771

<b>Clinical present.</b>	<b>Species / geographies</b>	<b>Goal</b>	<b>Use case</b>	<b>Rationale</b>
VL	<i>L. donovani/infantum</i> All geographies	Prophylactic	<b>a. VL prophylaxis</b>	<i>Broader impact</i>
		Therapeutic for HIV+	2 <sup>nd</sup> line treatment of VL in HIV+	<i>Deprioritized in view of the difficulty of treatment</i>
PKDL	South Asia and East Africa	Preventive	<b>Prevention of VL relapse (PKDL)</b>	<i>Seriousness of the diseases</i>
		Therapeutic	<b>1<sup>st</sup> line treatment of PKDL</b>	
CL	<i>L. tropica/aethiopica</i> East Africa and Middle East*	Prophylactic	<b>b. CL prophylaxis</b>	<i>Poor available treatment, uncontrolled</i>
		Therapeutic	<b>c. 1<sup>st</sup> line treatment of CL</b>	
	<i>L. (Viannia) braziliensis</i> Brazil / Americas	Prophylactic	<b>d. CL prophylaxis</b>	<i>Morbidity can be addressed through treatment</i>
		Therapeutic	<b>e. 1<sup>st</sup> line treatment of CL</b>	
	Other species	Prophylactic	CL prophylaxis	<i>Deprioritised in view of the limited size of the target population</i>
	Therapeutic	<b>1<sup>st</sup> line treatment of CL</b>		
MCL-DSL-DCL	All species	Therapeutic	m. 1 <sup>st</sup> line treatment of MCL-DSL-DCL	<i>Deprioritised in view of the limited size of the target population</i>

772

773 **Table 1 –Leishmaniasis vaccine use cases definition and prioritisation**

774

775

<i>Use case</i>	<b>Species / geographies</b>	<b>Delivery strategy/ies</b>
1. Prevention of VL	All geographies	Routine or campaign delivery in target at-risk populations (identified via endemicity mapping) Outbreak response via ring vaccination
2. Prevention of CL	All geographies	Routine or campaign delivery in target at-risk populations (identified via endemicity mapping)
3. Prevention of PKDL	All geographies	Adjunct(following) VL treatment
4. Treatment of PKDL		Same as current PKDL treatments

776

777 **Table 2 - Final set of use cases and delivery strategies**

778



<b>Indication</b>	<b>Target Population</b>	<b>Range</b>	<b>Sources</b>	<b>2018</b>
<b>Prevention of VL</b>	Population at risk of VL	Upper limit	WHO country estimates for 2014-15 and Pigott 2014	665,000,000
		Mid-point (base case)	WHO TRS 2010	404,000,000
		Lower limit	DNDi 2009	235,000,000
<b>Prevention of CL</b>	Population at risk of CL*	Upper limit	DNDi 2018	1,000,000,000
		Mid-point (base case)	WHO country estimates for 2014-15 and Pigott 2014	778,000,000
		Lower limit	WHO TRS 2010	392,000,000
<b>Prevention of PKDL</b>	VL cases	Upper limit	GBD, 2017, WER 2018, Alavar 2012	17,326
		Mid-point (base case)		13,800
		Lower limit		9,784
<b>Treatment of PKDL</b>	PKDL cases	Upper limit	WER 2018, Alavar 2012 with disease specific assumptions from Zijstra 2016, Kaye 2019, Mondel 2018	4,437
		Mid-point (base case)		3,462
		Lower limit		2,382

779

780 **Table 3: Target population \*30% of this population is assumed being also at risk of VL**

781

782

<b>Indication</b>	<b>Age for first dose</b>	<b>Duration of Protection</b>	<b>Nr. Doses per Series</b>	<b>Series (years of age)</b>
<b>VL prophylactic</b>	1 year	5 years	2	3 (1, 6 and 11)
<b>CL prophylactic</b>	1 year	5 years	2	3 (1, 6 and 11)
<b>CL/VL catch-up</b>			2	1
<b>PKDL therapeutic</b>	NA	Lifelong	1	1
<b>PKDL preventive</b>	NA	Lifelong	1	1

783

784 **Table 4 : Selected TPP assumptions relevant for the demand forecast**

785


<b>Indication</b>	<b>Delivery</b>	<b>Coverage</b>
<b>VL &amp; CL prophylactic</b>	Routine at 9 months-2 <sup>nd</sup> year of life	73%
	Routine at 6 years – 11 years	68%
	Routine for adults	45%
	Campaign delivery (including catch-up)	90%
<b>PKDL therapeutic &amp; preventive</b>	Following delivery of VL or PKDL treatment	93%

786

787 **Table 5: Delivery strategy and related coverage assumptions (source: WHO/UNICEF**  
788 **coverage estimates for 2018, WHO Measles campaign overview 2000-2020)**


789

790



791  
792  
793  
794  
795


**Figure 1: Logical framework of the demand forecast methodology**




807  
808 **Figure 2: Vaccine demand – total number of yearly doses required at global level for a**  
809 **vaccine with VL and CL indications (details of the methodology provided in the**  
810 **Supplementary Annex)**

811

812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827



**Figure 3: Vaccine demand: total number of doses for the period 2025-2040 stratified by delivery strategy (routine immunisation and catch-up campaign at start) and by indication (VL and CL)**



838  
839 **Figure 4: Vaccine demand – total number of yearly doses required at global level for a**  
840 **vaccine with PKDL therapeutic and preventative indications (in the scenario of a**  
841 **vaccine with VL indication also being available)**

842  
843